Home » Topics » BioWorld Science

BioWorld Science
RSS

Kaleido to advance KB-174 for HE based on topline data from study in patients with cirrhosis

Dec. 13, 2019

Soligenix initiates phase Ic study of RiVax

Dec. 13, 2019

Prescient presents promising interim phase Ib data for PTX-200 in ovarian cancer

Dec. 13, 2019

Positive interim safety data presented from ongoing phase Ib/IIa study of ATYR-1923

Dec. 13, 2019

Phase Ib data for carfilzomib plus chemotherapy in children with refractory ALL

Dec. 13, 2019

EGFL7 as a new therapeutic target in AML

Dec. 13, 2019

TDP-43-mediated splicing repression as a therapeutic target for ALS-FTD

Dec. 13, 2019

Phase I data presented for the novel M1 mAChR modulator VU-319

Dec. 13, 2019

Manageable safety and activity seen with GDC-0077 combination treatments in phase Ib study

Dec. 13, 2019

Improbability research yields path to HIV vaccine

Dec. 13, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....